CN111053815B - Traditional Chinese medicine composition for preventing acute gastric ulcer and preparation method thereof - Google Patents
Traditional Chinese medicine composition for preventing acute gastric ulcer and preparation method thereof Download PDFInfo
- Publication number
- CN111053815B CN111053815B CN202010046081.4A CN202010046081A CN111053815B CN 111053815 B CN111053815 B CN 111053815B CN 202010046081 A CN202010046081 A CN 202010046081A CN 111053815 B CN111053815 B CN 111053815B
- Authority
- CN
- China
- Prior art keywords
- gastric ulcer
- chinese medicine
- traditional chinese
- medicine composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 49
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 44
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 230000001154 acute effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 241000251468 Actinopterygii Species 0.000 claims abstract description 30
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 30
- 108010010803 Gelatin Proteins 0.000 claims abstract description 29
- 239000008273 gelatin Substances 0.000 claims abstract description 29
- 229920000159 gelatin Polymers 0.000 claims abstract description 29
- 235000019322 gelatine Nutrition 0.000 claims abstract description 29
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 29
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 210000002784 stomach Anatomy 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 13
- 235000014347 soups Nutrition 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 11
- 231100000397 ulcer Toxicity 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 208000008469 Peptic Ulcer Diseases 0.000 description 6
- KZFDVWZZYOPBQZ-UHFFFAOYSA-K bismuth;potassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KZFDVWZZYOPBQZ-UHFFFAOYSA-K 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000011906 peptic ulcer disease Diseases 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000004087 circulation Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000004833 fish glue Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for preventing acute gastric ulcer and a preparation method thereof, wherein the traditional Chinese medicine composition for preventing acute gastric ulcer is a preparation prepared from the following raw material medicines in parts by weight: 1-3 parts of red ginseng, 1-3 parts of fish gelatin and 0.5-1.5 parts of dried orange peel. Compared with the prior art, its beneficial effect lies in: the traditional Chinese medicine composition has the effects of protecting the integrity of gastric mucosa and relieving inflammatory reaction, can be applied to preventing acute gastric ulcer, has excellent application prospect in the aspect of development of medicines for preventing or treating acute gastric ulcer, is simple and convenient in preparation method, is easy to obtain medicinal materials, and is convenient for people to prepare and condition by themselves.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for preventing acute gastric ulcer and a preparation method thereof.
Background
Peptic ulcer is a common multiple disease and has the characteristic of repeated attack. The medicines such as a proton pump inhibitor, an antacid, a helicobacter pylori inhibitor, a gastric mucosa protective agent and the like are mostly adopted clinically for treating the peptic ulcer, and the methods have good near-term curative effects, but have unsatisfactory long-term curative effects and high recurrence rate, and have adverse reactions such as vomiting, nausea and the like. The commonly used anti-relapse drugs comprise an antacid, a gastric mucosa protective agent, an antibiotic and the like, and the clinical effects of the anti-relapse drugs are still controversial. Therefore, the development of a medicament for treating and preventing gastric ulcer with low side effect has important practical significance.
The pathogenesis of peptic gastric ulcer is deeply elucidated in traditional Chinese medicine, Guo Qing and the like consider that peptic ulcer is mainly caused by damage of three viscera of liver, spleen and stomach and weakness of spleen and stomach is the root of the disease. The famous old Zhou Fusheng Chinese medicine considers that the pathogenesis of peptic ulcer is characterized in that: spleen deficiency is the principal and deficiency heat is the secondary. Therefore, for peptic ulcer, the treatment principle of the traditional Chinese medicine is to tonify the middle-jiao and Qi, strengthen the spleen and harmonize the stomach. The traditional Chinese medicine starts from overall regulation, takes the characteristics of multi-way action mechanism and less side effect of a compound prescription, and has certain advantages and positions in the prevention and treatment of peptic ulcer.
Disclosure of Invention
The invention aims to overcome at least one defect (deficiency) of the prior art, provides a traditional Chinese medicine composition for preventing acute gastric ulcer, is used for solving the defect of the existing medicine in treating or preventing gastric ulcer, and has the effects of treating and preventing gastric ulcer and having light side effect.
The invention also aims to provide a preparation method of the traditional Chinese medicine composition for preventing acute gastric ulcer.
The technical scheme adopted by the invention is as follows:
the traditional Chinese medicine composition for preventing acute gastric ulcer is characterized by comprising a preparation prepared from the following raw material medicines in parts by weight: 1-3 parts of red ginseng, 1-3 parts of fish gelatin and 0.5-1.5 parts of dried orange peel.
The red ginseng in the traditional Chinese medicine composition is a cooked product of ginseng, is warm in nature and sweet and bitter in taste, has the effects of greatly invigorating primordial qi, recovering pulse, fixing desertion, tonifying qi and controlling blood, and is mainly used for treating body weakness and desertion, cold limbs and slight pulse, qi failing to control blood, metrorrhagia and metrostaxis. The dried orange peel is warm in nature, bitter and pungent in taste, has the effects of regulating qi, tonifying spleen, eliminating dampness and phlegm, and is mainly used for treating abdominal distension, anorexia, vomiting and diarrhea, cough and excessive phlegm in hospitals. Modern pharmacological research shows that ginsenoside, hesperidin and the like have the functions of strengthening stomach by fragrance, promoting gastric secretion, removing pneumatosis in digestive tract and enhancing immunity of organisms, thereby being beneficial to improving ulcer healing quality and reducing ulcer recurrence. The fish gelatin is a dry product of fish bubbles and swim bladders, has mild nature and sweet taste, has the effects of nourishing blood, stopping bleeding, tonifying kidney and securing essence, and can promote digestion function, stimulate appetite and improve appetite through modern medical research; replenishing qi and blood, promoting blood circulation, and enhancing immunity; and (4) supplementing collagen. Collagen peptide is the hydrolysate of collagen protein, has good absorption property, and is an important component for forming human skin and mucous membrane.
The traditional Chinese medicine composition provided by the technical scheme takes the functions of tonifying spleen and benefiting qi as a starting point to play a role in preventing gastric ulcer. The red ginseng in the traditional Chinese medicine composition is a monarch drug for tonifying qi and strengthening spleen, and can promote qi circulation to resist invasion of exogenous pathogenic factors; the fish gelatin can tonify spleen and stomach, is a ministerial drug, and is supplemented with red ginseng to strengthen qi and invigorate spleen; the dried orange peel is used as an assistant and guide drug and has the effects of strengthening the intestines and stomach, tonifying qi, lifting, harmonizing the stomach and eliminating dampness.
Further, the traditional Chinese medicine composition for preventing acute gastric ulcer is a preparation prepared from the following raw material medicines in parts by weight: 1 part of red ginseng, 1 part of fish gelatin and 1 part of dried orange peel.
Furthermore, the dosage form of the traditional Chinese medicine composition is tablets, granules, capsules or water-bindered pills.
Another object of the present invention is to provide a method for preparing the above-mentioned Chinese medicinal composition for preventing acute gastric ulcer, which comprises the following steps:
s1: preparing fish gelatin decoction filtrate
Taking 0.5-1.5 parts of fish gelatin blocks, adding 8-12 times of water, soaking for 1.5-3.5 h, then carrying out water bath twice in a water bath kettle at the temperature of 80-120 ℃, filtering, and combining filtrates of the two times;
s2: preparing decoction filtrate of red ginseng and dried orange peel
Taking 0.5-1.5 parts of red ginseng and dried orange peel respectively, adding 10 times of water, soaking for 15-45 min, heating and decocting for 0.8-1.2 h, repeating twice, filtering, and combining filtrates of the two times;
s3: mixing and concentrating
And mixing the decocted filtrate of the fish gelatin, the red ginseng and the dried orange peel, and evaporating and concentrating to 0.3-0.6 g/mL.
Furthermore, in the step S1, the water bath time is 1.5-4.5 h each time.
Further, the heating and decocting process in step S2 is as follows: boiling with strong fire, and then decocting with slow fire for 0.8-1.2 h.
Further, in step S3, the mixture is concentrated by a rotary evaporator.
Compared with the prior art, the invention has the beneficial effects that:
the invention provides a traditional Chinese medicine composition formula and a specific preparation method thereof, which can be applied to the prevention of acute gastric ulcer, and the traditional Chinese medicine composition has the effects of protecting the integrity of gastric mucosa and relieving inflammatory reaction, and has excellent application prospect in the aspect of the development of medicines for preventing or treating acute gastric ulcer; the preparation method is simple and convenient, the medicinal materials are easy to obtain, and the preparation and conditioning are convenient for people to prepare.
Drawings
FIG. 1 is a photograph showing the effect of red ginseng fish gelatin soup provided in example 1 on the gastric ulcer of mice induced by absolute ethanol.
Fig. 2 is a bar graph (Mean ± SD, n ═ 10) of the effect of red ginseng fish gelatin soup provided in example 1 on the gastric ulcer index of the mouse induced by absolute ethanol, and the corresponding numbers on the bar graph represent the ulcer index; p represents the statistical difference, # # P < 0.001 compared to Normal (Normal), P <0.05 compared to Model (Model), P < 0.01.
FIG. 3 is a photomicrograph of histopathological analysis of the red ginseng fish gelatin soup provided in example 1 on gastric ulcer in mice induced by absolute ethanol.
Fig. 4 is a histogram of the effect of red ginseng fish gelatin soup provided in example 1 on absolute ethanol induced gastric ulcer in mice, with # P < 0.001 in comparison with Normal group (Normal), and P <0.05 in comparison with Model group (Model), and P < 0.01.
In the above figures 1-4, the code HSYJT indicates the red ginseng fish gelatin soup of the composition of the present invention, and the code BPC indicates bismuth potassium citrate.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the detailed description and specific examples, while indicating the scope of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.
Example 1
The embodiment discloses a preparation method of a traditional Chinese medicine composition decoction for preventing acute gastric ulcer, which specifically comprises the following steps: sun drying fish gelatin, cutting into small pieces of 1cm × 1cm, soaking one part of fish gelatin in 10 times of water for 2.5 hr, adding into 100 deg.C water bath for 3 hr twice, filtering, and mixing filtrates; taking 1 part of each of red ginseng and dried orange peel, adding 10 times of water, soaking for 30min, boiling with strong fire, then decocting for lh with slow fire, repeating for 2 times, filtering, and combining the filtrates; the filtrates from the two decoctions were combined and concentrated by rotary evaporator to 0.45 g/mL.
In order to verify the effect of the red ginseng fish gelatin soup provided in this example on the mouse acute gastric ulcer model induced by absolute ethanol, the following experiments were performed.
1. Experimental Material
1.1 reagents
Bismuth Potassium Citrate (Bismuth Potassium Citrate) was purchased from the beauty pearl group pearl pharmaceutical factory. Anhydrous ethanol, available from Shanghai Aladdin Biotechnology GmbH.
1.2 Experimental instruments
BSA224S electronic analytical balance, sydows scientific instruments (beijing) ltd; PL-203 electronic balance, mettler-toledo instruments (shanghai) ltd; BX53 fluorescence microscope, Olympus, japan; canon Gl2 camera, Canon corporation, japan.
1.3 Experimental instruments
SPF-grade BALB/c mice, male, 18-22g, purchased from the laboratory animal center of Guangzhou university of traditional Chinese medicine (certificate number: SCXK (Guangdong) 2018-. The experimental animals are raised in cages and are adaptively raised for 5 days, and drinking water and eating are free during the experiment period. The temperature of the breeding environment is 22 days and 2 ℃, the relative humidity is 60%, and the breeding environment is irradiated for 12 hours every day and is circulated for 12 hours in the dark.
2. Experimental methods
2.1 preparation of the experiment
SPF male BALB/c mice were weighed before the start of the experiment and randomly divided by body weight into a Normal group (Normal), a Model group (Model), a bismuth potassium citrate group (BPC, 30mg/kg), a red ginseng fish gelatin soup low, medium and high dose groups (HSYJT, corresponding to 0.75, 1.5, 3g/kg), and 11 mice per group. After grouping, labeling, each mouse body weight was weighed again, recorded and the corresponding dose volume (0.2mL/10g) was calculated. Except for the normal group and the model group, the other groups were given the corresponding drug treatments, 1 time per day by gavage, and 13 days continuously. After l hours after the last administration, each mouse is perfused with absolute ethanol (0.1mL/20g) to cause acute gastric mucosal injury, and the mice need to fast for 24 hours before model building and drink water freely.
After 1 hour of intragastric administration of absolute ethanol, each mouse was euthanized, the whole stomach was taken out, the stomach wall was cut along the greater curvature of the stomach, the contents of the stomach were washed, and the stomach tissue was developed for fixation and photographing. And (4) calculating the gastric ulcer index according to a method reported in a literature, and evaluating the degree of ethanol-induced gastric mucosal injury.
2.2 determination of the results
Cumulative scores were scored by observing erosion in gastric mucosal tissue, length of the foci: 0 minute: normal; 1 minute: 1-5 bleeding points (<1 mm); and 2, dividing: 6-10 bleeding points (<2 mm); and 2, dividing: small streak bleeding (<2 mm); and 3, dividing: >10 bleeding points (<1 mm); and 3, dividing: medium length streak bleeding (2-4 mm); and 4, dividing: bleeding in long strips (>4 mm); if the width > Imm, this term is X2, the ulcer index and the ulcer inhibition rate are calculated according to the formulas (2-1) and (2-2), respectively:
UI＝∑{1(a)+1(b)+1(c)}
ulcer inhibition (%) as ═ UI model group-UI experimental group/UI model group × 100%
The same part was used to take a stomach tissue of 5mm × 5mm, fixed in a 4% paraformaldehyde solution, dehydrated, sectioned and HE-stained, and observed under a microscope and photographed.
Histological pathology scoring of gastric mucositis and extent of injury was performed and the total score calculated in reference:
a. degree of epithelial cell damage: epithelial cells were not damaged-0 min; epithelial cells were slightly damaged-1 point; epithelial moderate damage-2 points; epithelial cells were severely damaged-3 points;
b. degree of edema: no edema, score-0; mild edema-1 point; moderate edema-2 points; high edema-3 points, severe edema-4 points;
c. inflammatory cell production: no inflammatory cells produced-0 points; a small number of inflammatory cells produced-1 point; moderate levels of inflammatory cell production-2 points;
the total score varies from 0 (normal) to 9 (severe gastric ulcer).
2.3 statistical treatment
The data are expressed as mean ± standard deviation (mean ± SD), plotted using Graphpad Prism 5.02 software, and the difference in significance is expressed using P <0.05 as the standard. Comparison of normal versus model groups, independent sample T test (Student's test) was used. # compared to the normal group: p < 0.01: compared to the model group,: p <0.05, x: p < 0.01.
3. Results of the experiment
Table 1 shows the effect of red ginseng fish gelatin soup provided in example 1 on the inhibition rate of gastric ulcer in mice induced by absolute ethanol:
as shown in fig. 1, fig. 2 and table 1, the experimental results showed that almost no macroscopic damage was observed in the normal group. Compared with the normal group, the gastric mucosa of the intragastric anhydrous ethanol group has serious damage, obvious bleeding appears, the bleeding is in a strip cord shape, the ulcer index is 16.77 +/-8.55, and the success of the gastric ulcer molding induced by the ethanol is shown. The ulcer condition was significantly relieved by pre-administration of bismuth potassium citrate, with an ulcer index of 6.90 mg 6.26 (inhibition of 58.87%). The ulcer index was reduced to different extents by pre-administration of red ginseng fish gelatin soup (0.75, 1.5 and 3 g/kg). In addition, the red ginseng fish gelatin soup group with the dosage of 3g/kg has the lowest ulcer index of 7.91 and 4.59, and the highest inhibition rate (52.86%).
As shown in fig. 3 and fig. 4, histological observation shows that the normal gastric mucosa of the mouse has complete structure, the cells of the mucosa layer are arranged closely and regularly, the epithelium does not fall off, the gland does not have damage, and inflammatory cell infiltration and edema do not exist in the lamina propria (the total score is 1.00 +/-0.58); the gastric mucosa of the model group has deeper damage and larger area, a large amount of inflammatory cell infiltration exists, a large amount of epithelial cells fall off and are eroded, cells of the mucosa layer fall off and partially lose cell structures, the arrangement is disordered, and edema exists in the inherent layer (the total score is 6.67 +/-0.58); the bismuth potassium citrate group has more complete gastric mucosa, lighter epithelial exfoliation, orderly arrangement of mucosa layer cells and less inflammation cells of an inherent layer (the total score is 2.67 +/-0.58); the red ginseng fish glue soup pre-administration group has prevention effects of different degrees on pathological injuries, wherein the red ginseng fish glue soup high-dose group (3g/kg) has obvious effects, gastric mucosa is kept intact, cells of the mucosa layer are arranged closely, epithelium is slightly fallen off, and inflammatory cell infiltration is rarely seen in the lamina propria (the total score is 3.00 +/-0.57).
Example 2
The embodiment discloses a preparation method of a traditional Chinese medicine composition tablet for preventing acute gastric ulcer, which specifically comprises the following steps: pulverizing Ginseng radix Rubri 240g, fish gelatin 240g and pericarpium Citri Tangerinae 120g into fine powder, mixing with appropriate amount of sucrose, starch, dextrin and silica gel micropowder, granulating, pressing into 1000 tablets, coating with sugar coating or film coating, and packaging. The product has a net weight of 0.8g, and can be taken with warm water 3 times a day, 4 tablets each time. The product has the effects of strengthening spleen and nourishing stomach, promoting qi circulation and harmonizing stomach; can be used for treating gastralgia, abdominal distention, gastric ulcer and duodenal ulcer.
Example 3
The embodiment discloses a preparation method of a traditional Chinese medicine composition granule for preventing acute gastric ulcer, which specifically comprises the following steps: the three medicinal materials of 240g of red ginseng, 240g of fish gelatin and 120g of dried orange peel are crushed into fine powder, and the fine powder is mixed with a proper amount of sucrose powder, granulated, dried and mixed evenly to prepare 1000g, and the mixture is subpackaged into bags. The product is taken 3 times a day in one bag with 4g of warm water, and one bag is used for one time. The product has the effects of strengthening spleen and nourishing stomach, promoting qi circulation and harmonizing stomach; can be used for treating gastralgia, abdominal distention, gastric ulcer and duodenal ulcer.
Example 4
The embodiment discloses a preparation method of a traditional Chinese medicine composition capsule for preventing acute gastric ulcer, which specifically comprises the following steps: the three medicinal materials of 240g of red ginseng, 240g of fish gelatin and 120g of dried orange peel are crushed into fine powder, and the fine powder is mixed with a proper amount of sucrose powder, dried, mixed and encapsulated to prepare 1000 capsules, and each capsule contains 0.8g of the powder. The product is taken with warm water, 3 times a day, 4 granules at a time. The product has the effects of strengthening spleen and nourishing stomach, promoting qi circulation and harmonizing stomach; can be used for treating gastralgia, abdominal distention, gastric ulcer and duodenal ulcer.
Example 5
The embodiment discloses a preparation method of a traditional Chinese medicine composition water pill for preventing acute gastric ulcer, which specifically comprises the following steps: the preparation method comprises the following steps of crushing 240g of red ginseng, 240g of fish gelatin and 120g of dried orange peel into fine powder, sieving, uniformly mixing, adding clinically acceptable auxiliary materials, making pills, drying and selecting pills. The product is taken orally with 1g per 20 pills, 3 times a day and 5g once. The product has the effects of strengthening spleen and nourishing stomach, promoting qi circulation and harmonizing stomach; qianwei Gao ache, epigastric fullness and distention, gastric ulcer and duodenal ulcer.
It should be understood that the above-mentioned embodiments of the present invention are only examples for clearly illustrating the technical solutions of the present invention, and are not intended to limit the specific embodiments of the present invention. Any modification, equivalent replacement, and improvement made within the spirit and principle of the present invention claims should be included in the protection scope of the present invention claims.
Claims (7)
1. The traditional Chinese medicine composition for preventing acute gastric ulcer is characterized by being prepared from the following raw material medicines in parts by weight: 1-3 parts of red ginseng, 1-3 parts of fish gelatin and 0.5-1.5 parts of dried orange peel.
2. The traditional Chinese medicine composition for preventing acute gastric ulcer according to claim 1, which is a preparation prepared from the following raw material medicines in parts by weight: 1 part of red ginseng, 1 part of fish gelatin and 1 part of dried orange peel.
3. The traditional Chinese medicine composition for preventing acute gastric ulcer as claimed in claim 2, wherein the dosage form of the traditional Chinese medicine composition is tablet, granule, capsule or watered pill.
4. The preparation method of the traditional Chinese medicine composition for preventing acute gastric ulcer, according to any one of claims 1 to 3, is characterized by comprising the following steps:
s1: preparing fish gelatin decoction filtrate
Taking 0.5-1.5 parts of fish gelatin blocks, adding 8-12 times of water, soaking for 1.5-3.5 h, then carrying out water bath twice in a water bath kettle at 80-120 ℃, filtering, and combining filtrates of the two times;
s2: preparing decoction filtrate of red ginseng and dried orange peel
Taking 0.5-1.5 parts of red ginseng and dried orange peel respectively, adding 10 times of water, soaking for 15-45 min, heating and decocting for 0.8-1.2 h, repeating twice, filtering, and combining filtrates of the two times;
s3: mixing and concentrating
And mixing the decocted filtrate of the fish gelatin, the red ginseng and the dried orange peel, and evaporating and concentrating to 0.3-0.6 g/mL.
5. The preparation method of the traditional Chinese medicine composition for preventing acute gastric ulcer, according to claim 4, is characterized in that the water bath time in step S1 is 1.5-4.5 h each time.
6. The method for preparing a Chinese medicinal composition for preventing acute gastric ulcer as claimed in claim 4, wherein the decocting process in step S2 is as follows: boiling with strong fire, and then decocting with slow fire for 0.8-1.2 h.
7. The method for preparing a Chinese medicinal composition for preventing acute gastric ulcer according to any one of claims 4, 5 or 6, wherein the concentration in step S3 is performed by using a rotary evaporator.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010046081.4A CN111053815B (en) | 2020-01-16 | 2020-01-16 | Traditional Chinese medicine composition for preventing acute gastric ulcer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010046081.4A CN111053815B (en) | 2020-01-16 | 2020-01-16 | Traditional Chinese medicine composition for preventing acute gastric ulcer and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111053815A CN111053815A (en) | 2020-04-24 |
| CN111053815B true CN111053815B (en) | 2021-10-01 |
Family
ID=70307411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010046081.4A Active CN111053815B (en) | 2020-01-16 | 2020-01-16 | Traditional Chinese medicine composition for preventing acute gastric ulcer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111053815B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1217684C (en) * | 2002-10-29 | 2005-09-07 | 内蒙古宇航人高技术产业有限责任公司 | Chinese medicine for repairing gastric mucosa |
| CN104998140B (en) * | 2015-08-10 | 2018-09-07 | 刘梅霞 | A kind of Chinese medicine preparation for chronic gastric ulcer |
| CN106166279A (en) * | 2016-04-17 | 2016-11-30 | 浙江宇晨药业有限公司 | A kind of blood-activating analgetic treatment gastric ulcer medicated tea and preparation processing method |
| CN107485659B (en) * | 2016-09-09 | 2020-11-10 | 郑州泰丰制药有限公司 | A pharmaceutical composition for treating gastric ulcer and duodenal ulcer |
-
2020
- 2020-01-16 CN CN202010046081.4A patent/CN111053815B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111053815A (en) | 2020-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885857B (en) | Extraction method of periplaneta americana extract for treating peptic ulcer | |
| CN100384463C (en) | Medicine for trenting flooding and spotting, haematemesis and homafecia | |
| CN100417407C (en) | Pharmaceutical composition for treating oral ulcer and preparation method and application thereof | |
| CN106822579B (en) | Composition with osteoporosis treatment effect and preparation method and application thereof | |
| CN105213256A (en) | A kind of Shu Min dispels red toner/smoothing toner and preparation method thereof | |
| CN100431568C (en) | Chinese medicine for treating puerperal hypogalactia | |
| CN104666794A (en) | Pollen royal jelly drink as well as preparation method and application thereof | |
| CN111053815B (en) | Traditional Chinese medicine composition for preventing acute gastric ulcer and preparation method thereof | |
| CN103893613B (en) | A kind of medicine treating oral ulcer and preparation method | |
| CN103977206A (en) | Traditional Chinese medicine preparation capable of improving gastrointestinal digestive function and production method thereof | |
| CN1961951A (en) | Chinese medicinal formulation for treating hydrocephalus | |
| CN102139081B (en) | Chinese medicinal composition and preparation for treating recurrent oral ulcer and preparation method thereof | |
| CN100534498C (en) | Pharmaceutical composition used for chronic atrophic gastritis and preparation method thereof | |
| CN105497677A (en) | Traditional Chinese medicine composition for promoting gastric disease rehabilitation | |
| CN1279929C (en) | Chinese medicine for treating facial paralysis, preparing method and use | |
| CN107854662A (en) | A kind of Chinese medicine preparation for treating cirrhotic ascites and preparation method thereof | |
| CN101972378B (en) | Traditional Chinese medicine for treating gout | |
| CN101053595B (en) | Medicinal preparation for treating constipation and its preparing method | |
| CN102028895A (en) | Medicinal composition with antioxidant activity and blood vessel and blood cleaning antioxidant and/or protective agent | |
| CN101716202B (en) | Traditional Chinese medicine containing radix achyranthis bidentatae for treating facioplegia as well as preparation method and use | |
| CN105031587A (en) | Chinese herba preparation for curing gastrointestinal diseases | |
| CN106266427A (en) | A kind of Traditional Chinese medicinal liquor treating nephropathy and preparation method thereof | |
| CN105943955A (en) | Traditional Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
| CN105267929A (en) | Micro-powder capsule for treating peptic ulcer | |
| CN1289122C (en) | Medicinal composition for treating psoriasis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 510730 No. 8, Huafeng Road, Yonghe Economic Zone, Guangzhou Economic and Technological Development Zone, Guangdong Province Applicant after: Bainian Tongkang Pharmaceutical Group Co.,Ltd. Address before: 510000 No. 8, Huafeng Road, Yonghe Economic Zone, Guangzhou Economic and Technological Development Zone, Guangdong Province Applicant before: GUANGZHOU TONGKANG PHARMACEUTICAL Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230922 Address after: Room 406, 4th Floor, Building 3, No. 8 Huafeng Road, Huangpu District, Guangzhou City, Guangdong Province, 510700 Patentee after: GUANGDONG DAODI CHINESE MEDICINE Co.,Ltd. Address before: 510730 No. 8, Huafeng Road, Yonghe Economic Zone, Guangzhou Economic and Technological Development Zone, Guangdong Province Patentee before: Bainian Tongkang Pharmaceutical Group Co.,Ltd. |
|
| TR01 | Transfer of patent right |